Dynavax Initiates US-Based Phase 1 Clinical Trial of HEPLISAV Hepatitis B Vaccine in Dialysis Population
1st Nov 2005, 17:38 GMT
Dynavax Technologies Corp announced the initiation of a Phase 1 clinical trial of HEPLISAV, its ISS-based hepatitis B vaccine in patients with end-stage renal failure.
Dynavax Initiates US-Based Phase 1 Clinical Trial of HEPLISAV Hepatitis B Vaccine in Dialysis Population related news:
- Dynavax Initiates US-Based Phase 1 Clinical Trial of HEPLISAV(TM) Hepatitis B Vaccine in Dialysis Population — PR Newswire: All Releases
- Nabi vaccine fails clinical trial — bizjournals.com Health Care:Pharmaceuticals headlines
- Nabi Biopharmaceuticals Announces Results of StaphVAX Confirmatory Phase III Clinical Trial — Nephrology/ Dialysis News from StratCenter.com
- Hepatitis A Vaccine Advised for Toddlers — WebMD Health Headlines
- Patient Enrollment Permanently Discontinued in Investigational Clinical Trial of REOPRO(R) (abciximab) for Acute Ischemic Stroke — DBusiness News - Indianapolis
- Phase I Study of High Dose Weekly ABRAXANE Published in Journal of Clinical Oncology: Responses Achieved in Patients With Taxol Refractory Ovarian Cancer and Lung Cancer — Radiology News from StratCenter.com
- Sangart Announces Positive Phase II Results for Hemospan Oxygen Transport Agent; Presentation of Results th Critical Care Congress — Orthopedics News from StratCenter.com
- Study shows that dialysis patients often have close family members also on dialysis — EurekAlert! - Medicine and Health
- Alnylam files for human clinical trial — Latest news from Boston Business Journal
- Advanced Magnetics Data Monitoring Committee Recommends Continuation of Phase III Studies for Ferumoxytol — Nephrology/ Dialysis News from StratCenter.com
Latest news from Nephrology/ Dialysis News from StratCenter.com:
- New Data Show ACTOS Halted Progression of Atherosclerosis as Indicated by CIMT in Patients with Type 2 Diabetes
- Ruboxistaurin Reduced Vision Loss in Patients With Moderate to Severe Non-Proliferative Diabetic Retinopathy in a New Study
- Aksys Reports Q3 2006 Financial Results
- Altus Pharmaceuticals Announces Presentation of ALTU-238 Phase II Data at Int'l Congress of Growth Hormone and Insulin-Like Growth Factor Research Societies
- Opexa Reports Q3 Financial Results
- Treatment of Diabetic Foot Ulcers Addressed at Upcoming American Heart Assoc Meeting
- Weight Loss Surgery Assists in Eliminating, Avoiding Type 2 Diabetes; American Institute of Gastric Banding Recognizes November as Nat'l Diabetes Month
- Federal Economic Development Agency Enlists Support of African-American Churches in the IL Delta
- Federal Economic Development Agency Enlists Support of African-American Churches in the MS Delta
- Federal Economic Development Agency Enlists Support of African-American Churches in the LA Delta